TY - JOUR
T1 - Treatment of nontuberculous mycobacterial pulmonary disease
T2 - An official ats/ers/escmid/idsa clinical practice guideline
AU - Daley, Charles L.
AU - Iaccarino, Jonathan M.
AU - Lange, Christoph
AU - Cambau, Emmanuelle
AU - Wallace, Richard J.
AU - Andrejak, Claire
AU - Böttger, Erik C.
AU - Brozek, Jan
AU - Griffith, David E.
AU - Guglielmetti, Lorenzo
AU - Huitt, Gwen A.
AU - Knight, Shandra L.
AU - Leitman, Philip
AU - Marras, Theodore K.
AU - Olivier, Kenneth N.
AU - Santin, Miguel
AU - Stout, Jason E.
AU - Tortoli, Enrico
AU - Van Ingen, Jakko
AU - Wagner, Dirk
AU - Winthrop, Kevin L.
N1 - Publisher Copyright:
© The Author(s) 2020.
PY - 2020/8/15
Y1 - 2020/8/15
N2 - Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. This guideline focuses on pulmonary disease in adults (without cystic fibrosis or human immunodeficiency virus infection) caused by the most common NTM pathogens such as Mycobacterium avium complex, Mycobacterium kansasii, and Mycobacterium xenopi among the slowly growing NTM and Mycobacterium abscessus among the rapidly growing NTM. A panel of experts was carefully selected by leading international respiratory medicine and infectious diseases societies (ATS, ERS, ESCMID, IDSA) and included specialists in pulmonary medicine, infectious diseases and clinical microbiology, laboratory medicine, and patient advocacy. Systematic reviews were conducted around each of 22 PICO (Population, Intervention, Comparator, Outcome) questions and the recommendations were formulated, written, and graded using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. Thirty-one evidence-based recommendations about treatment of NTM pulmonary disease are provided. This guideline is intended for use by healthcare professionals who care for patients with NTM pulmonary disease, including specialists in infectious diseases and pulmonary diseases.
AB - Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. This guideline focuses on pulmonary disease in adults (without cystic fibrosis or human immunodeficiency virus infection) caused by the most common NTM pathogens such as Mycobacterium avium complex, Mycobacterium kansasii, and Mycobacterium xenopi among the slowly growing NTM and Mycobacterium abscessus among the rapidly growing NTM. A panel of experts was carefully selected by leading international respiratory medicine and infectious diseases societies (ATS, ERS, ESCMID, IDSA) and included specialists in pulmonary medicine, infectious diseases and clinical microbiology, laboratory medicine, and patient advocacy. Systematic reviews were conducted around each of 22 PICO (Population, Intervention, Comparator, Outcome) questions and the recommendations were formulated, written, and graded using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. Thirty-one evidence-based recommendations about treatment of NTM pulmonary disease are provided. This guideline is intended for use by healthcare professionals who care for patients with NTM pulmonary disease, including specialists in infectious diseases and pulmonary diseases.
KW - Mycobacterium abscessus
KW - Mycobacterium avium complex
KW - Mycobacterium kansasii
KW - Mycobacterium xenopi
KW - Nontuberculous
UR - http://www.scopus.com/inward/record.url?scp=85089612675&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089612675&partnerID=8YFLogxK
U2 - 10.1093/cid/ciaa241
DO - 10.1093/cid/ciaa241
M3 - Article
C2 - 32628747
AN - SCOPUS:85089612675
SN - 1058-4838
VL - 71
SP - E1-E36
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 4
ER -